We are live on ! Find out more
GILD icon

Gilead Sciences

1,525 hedge funds and large institutions have $66.4B invested in Gilead Sciences in 2017 Q1 according to their latest regulatory filings, with 133 funds opening new positions, 601 increasing their positions, 701 reducing their positions, and 157 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.66% less ownership

Funds ownership: 75.43%74.76% (-0.66%)

3% less funds holding

Funds holding: 1,5731,525 (-48)

3% less funds holding in top 10

Funds holding in top 10: 9188 (-3)

7% less capital invested

Capital invested by funds: $71.2B → $66.4B (-$4.83B)

14% less repeat investments, than reductions

Existing positions increased: 601 | Existing positions reduced: 701

15% less first-time investments, than exits

New positions opened: 133 | Existing positions closed: 157

35% less call options, than puts

Call options by funds: $1.45B | Put options by funds: $2.24B

Holders
1,525
Holders Change
-48
Holders Change %
-3.05%
% of All Funds
37.95%
Holding in Top 10
88
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-3.3%
% of All Funds
2.19%
New
133
Increased
601
Reduced
701
Closed
157
Calls
$1.45B
Puts
$2.24B
Net Calls
-$793M
Net Calls Change
-$355M
Name Holding Trade Value Shares
Change
Change in
Stake
PIM
1051
Profit Investment Management
Maryland
$771K -$59.4K -845 -7%
WIP
1052
Wellesley Investment Partners
Massachusetts
$769K +$167K +2,382 +27%
LIM
1053
Leavell Investment Management
Alabama
$766K -$623K -8,865 -44%
CA
1054
Cullinan Associates
Kentucky
$764K -$2.32M -32,972 -75%
BPGAM
1055
BTG Pactual Global Asset Management
Bermuda
$760K +$787K +11,187 New
MPM
1056
Meritage Portfolio Management
Kansas
$759K -$24.6K -350 -3%
SCA
1057
Sippican Capital Advisors
Massachusetts
$757K +$236K +3,359 +43%
BIM
1058
Baldwin Investment Management
Pennsylvania
$752K -$14.1K -200 -2%
FCCM
1059
First City Capital Management
Georgia
$746K +$3.66K +52 +0.5%
NED
1060
Nancy E. Dempze
$738K -$3.52K -50 -0.5%
BUB
1061
BBVA USA Bancshares
Texas
$737K -$119K -1,698 -14%
JGC
1062
J. Goldman & Co
New York
$734K +$759K +10,800 New
HR
1063
Howe & Rusling
New York
$730K -$195K -2,772 -21%
TF
1064
Tompkins Financial
New York
$729K +$17.6K +251 +2%
WAM
1065
Wealthspire Advisors (Maryland)
Maryland
$729K +$352K +5,000 +87%
GWM
1066
Geneos Wealth Management
Colorado
$726K -$106K -1,512 -12%
IAA
1067
Independent Advisor Alliance
North Carolina
$723K -$854K -12,150 -53%
RFS
1068
Rockefeller Financial Services
New York
$720K -$384K -5,458 -34%
SAS
1069
Stelac Advisory Services
New York
$715K +$180K +2,558 +32%
OCM
1070
Orleans Capital Management
Louisiana
$713K
WPW
1071
Waldron Private Wealth
Pennsylvania
$711K +$123K +1,752 +20%
BVDMP
1072
Bedrijfstakpensioenfonds Voor De Media PNO
Netherlands
$706K
DLA
1073
Douglas Lane & Associates
New York
$706K +$16.5K +235 +2%
HSA
1074
HBK Sorce Advisory
Pennsylvania
$703K -$147K -2,087 -17%
PCM
1075
Palisade Capital Management
New Jersey
$700K -$21.1K -300 -3%

GILD Hedge Fund Activity: Q1 2017 in Review

1,525 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q1 2017, worth a combined $66.4B — down 6.8% from $71.2B a quarter earlier.

Sellers outnumbered buyers: 157 funds closed out of GILD and 133 opened new positions — a net loss of 24 holders — while 701 trimmed existing stakes and 601 added.

The largest buyer was BlackRock, adding an estimated $6.99B. The largest seller was Fidelity Investments, cutting an estimated $1.15B.

  • 1,525 institutional investors held Gilead Sciences (GILD) as of Q1 2017, down from 1,573 in Q4 2016.
  • Funds reported $66.4B of Gilead Sciences stock for Q1 2017, down 6.8% quarter-over-quarter.
  • 133 funds opened new Gilead Sciences positions in Q1 2017 and 157 closed out, a net change of -24 holders.
  • The largest Gilead Sciences buyer in Q1 2017 was BlackRock, an estimated $6.99B added.
  • The largest Gilead Sciences seller in Q1 2017 was Fidelity Investments, an estimated $1.15B sold.

Based on aggregated 13F filings for Q1 2017.